To determine the intrinsic responsiveness of AML cell lines, the first generation BH3 mimetic that inhibits both Bcl-2 and Bcl-XL, was used to treat a panel of lines at nM concentrations. This evidence concerns the gene BCL2 and acute myeloid leukemia.